Why Beam Therapeutics Stock Zoomed 17% Higher Today

Beam Therapeutics (BEAM 16.47%) stock thundered out of the gate this week, rising to close nearly 17% higher in price on Monday. Much of this was due to a recommendation upgrade from a prominent bank. By contrast, the S&P 500 only eked out a 0.8% gain.JPMorgan Chase gets more bullish on BeamWell before market open, JPMorgan Chase's (JPM 0.26%) Eric Joseph moved his recommendation on Beam one peg up to overweight (buy, in other words) from the preceding neutral. He also topped off his price target on the bio ...